• About Us
    • TWi USA
    • USA Team
  • Our Products
  • For Customers
    • Authorized Distributors
    • TWi USA State Licenses
    • Return Goods Policy
    • Customer Service Contacts
  • For Patients
    • Adverse Event Reporting, Product Complaints & Medical Information(FOr USA Only)
    • Sorafenib Co-Pay Savings Program
  • Contact Us

buPROPion Hydrochloride Extended-Release Tablets (XL)

Cyclobenzaprine Hydrochloride Extended-Release Capsules

Diltiazem Hydrochloride Extended-Release Capsules

Dimethyl Fumarate Delayed-Release Capsules

Donepezil tablets

Fenofibric Acid Delayed-Release Capsules

Fluphenazine Hydrochloride Tablets, USP

Guanfacine Hydrochloride Extended-Release Tablets

Hydroquinone Cream

MegestrolAcetate Oral Suspension

Metformin Hydrochloride Extended Release Tablets

Metoprolol Succinate Extended-Release Tablets

Mycophenolic Acid DR Tablets

Nifedipine Extended-Release tablets

Paclitaxel Protein-Bound Particles for Injectable Suspension - (Albumin-Bound)

Propafenone Hydrochloride Extended-Release Capsules, USP

Sevelamer Carbonate Tablets

Sorafenib Tablets, USP

Testosterone Gel, 1.62% CIII

Terbutaline Sulfate tablets

Testosterone Topical Solution CIII, USP

Home > Products > For the United States

Megestrol Acetate Oral Suspension, USP

Route
Oral
Dosage form
Suspension
Strength
125mg/ml
Rx/OTC
Rx
Indication
For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS)
TE Rating
AB
Reference Listed Drug
Megace® ES
ANDA#
203139
Strength Form Product Description How Supplied NDC Number HDMA
Sheets
PI SDS
125 mg/ ml Suspension Milky-white suspension Bottle of 150ml 24979-041-13

BackTop

©Copyright 2016 TWi Pharmaceuticals USA, Inc. All rights reserved.